Login to Your Account

Ablynx Pads Cash Reserves to Push RA Drug into Phase IIb

By Nuala Moran
Staff Writer

Wednesday, March 6, 2013
Ablynx NV raised €31.5 million (US$41 million) in a private placement, boosting cash reserves to around €90 million and allowing the company to progress development of its next-generation rheumatoid arthritis (RA) product ALX-0061 into Phase IIb, while negotiating with potential partners.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription